ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4

Journal of Coastal Life Medicine

Effect and Potential Mechanism of First-Line Oral Antitubercular Therapy Safety and Effectiveness with Adjuvant Drugs

Received: 24 October 2022, **Revised:** 22 November 2022, **Accepted:** 26 December 2022

Dr.V.M.Thorat.
Professor& HOD. Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad – 415110,Maharashtra

Dr. D.V. Sarvaiya.
Tutor. Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad – 415110,Maharashtra

Dr. Akash Devi.
Tutor. Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed ToBe University",Karad – 415110,Maharashtra

Key Words:
Antitubercular Therapy, First-Line, Adjuvant Drugs, Effect, Safety

Abstract:
The purpose of this study is to examine the impact of adjuvant drugs on the safety and efficacy of first-line oral antitubercular therapy. This study was conducted at the pulmonary medicine outpatient department in Delhi, India, and was prospective and non-interventional. Adverse events occurred in 9 patients (18.75%) who did not take metformin and in 7 patients (14.58%) who did take it. (Chi-square test, P=.84) There was no discernible difference between the two groups. All of the reported side effects and problems involved the digestive system and were rather minor in nature. Given that our results suggest metformin might be used as an adjuvant antitubercular drug, particularly in those who have had both diabetes and TB, they are important for many stakeholders and policymakers.

1. Introduction:

The first-line oral antitubercular therapy (ATT), which includes the medications isoniazid, rifampin, pyrazinamide, and ethambutol, is the recommended course of treatment for tuberculosis (TB). To increase the efficacy of the normal ATT regimen or lower the possibility of side effects, adjuvant medicines may be added (Sugawara, 2004).

First-line oral ATT's efficacy and safety have been thoroughly investigated and proven in clinical studies and real-world situations. The drugs in the typical regimen are bactericidal and work via several mechanisms to target various phases of the TB life cycle. The most crucial medications in the regimen are isoniazid and rifampin since they are both very potent and quickly eradicate TB germs (Thillai, 2014).

Adjuvant medications may be used to treat a variety of problems that might come up during ATT, including as drug toxicity, drug resistance, and subpar therapy results. For instance, steroids may be used to control inflammation and avoid problems in patients with severe TB illness or TB meningitis, and vitamin B6 (pyridoxine) can be administered together with isoniazid to prevent peripheral neuropathy (Mase, et al., 2013).

Depending on the particular treatment, adjuvant medications have different mechanisms of action. For instance, supplementing with vitamin B6 helps halt the onset of peripheral neuropathy since it is a crucial coenzyme for the metabolism of isoniazid. Because steroids have anti-inflammatory characteristics, they help lessen edoema and inflammation in the brain and other TB-affected organs (Nahid et al., 2016).

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Overall, first-line oral ATT is safe and effective, and the use of adjuvant medications may assist improve treatment results and reduce the risk of side effects. It is crucial to get medical advice before using adjuvant medications and to keep a watchful eye out for any possible drug interactions or negative effects (Lange et al., 2019; WHO, 2019).

The usual therapy for TB is antitubercular therapy (ATT). The first-line oral ATT regimen includes of a mix of drugs that are bactericidal and target several phases of the TB life cycle using various modes of action. Isoniazid, rifampin, pyrazinamide, and ethambutol are all parts of the conventional treatment plan. Drug-susceptible TB therapy normally lasts six months, and in order for it to be successful, patients must follow their treatment plan exactly.

Several clinical studies and real-world situations have shown that ATT is effective. ATT is very successful in treating TB and halting the development of drug-resistant TB. However, the extent of the condition, the prevalence of medication resistance, and the patient's compliance with the prescribed regimen all affect how well the therapy works.

The typical ATT regimen may be supplemented with adjuvant medications to address certain problems that may come up during therapy, such as drug toxicity, drug resistance, and subpar treatment results. Steroids may be administered to minimise inflammation and avoid problems in patients with severe TB illness or TB meningitis, for instance, and vitamin B6 (pyridoxine) can be given together with isoniazid to prevent peripheral neuropathy (Sterling, et al., 2019).

The usual TB therapy, ATT, is quite successful at both treating the illness and avoiding drug resistance. Drug adjuvants may be used to improve treatment results and reduce the possibility of negative side effects. It is crucial that patients follow their treatment plan, and medical professionals should keep a careful eye out for any possible medication interactions or negative effects.

2. Research Methodology

Research Design:

This was a prospective, observational research done in an outpatient clinic for pulmonary medicine in Delhi, India. Patients were recruited from April 2018 to July 2019 and will be tracked till End-of-Training (EOT). All participants freely provided written informed consent. All participants were guaranteed to remain anonymous and in perfect confidence.

Size of the Sample:

Sixty participants were given oral metformin and the other sixty were given different anti-diabetic drugs for their TB and diabetes.

Data Sources

- Data Record Sheet
- Identity Card
- Laboratory Register
- Laboratory reports
- Physicians prescribing records
- Survey Form/Questionnaire
- TB Register
- Treatment Card

TB and blood glucose Diagnosis measurements

The Ziehl-Neelsen staining technique was used to check the sputum of PTB patients admitted to the hospital for acid fast bacilli (AFB). There were cases of PTB with positive sputum findings. Sputum smears were also analysed as part of the AFB diagnosis. Patients with tuberculosis whose sputum tests have come back positive and who have been diagnosed with type 2 diabetes based on their most recent medications and medical records were included. HbA1c levels were checked at the start of treatment, when the intensive phase was over, and after the treatment was complete. The American Diabetes Association (ADA, 2015) defined managed diabetes as a HbA1c of less than 7% and uncontrolled diabetes as a HbA1c of more than 7%.

Parameters used to evaluate Metformin's potential antitubercular mechanism

When a person in Delhi, India, is considered, it is assumed that he or she is a patient with TB. Based on whether or not they received metformin, participants were categorised as "non-metformin therapy" (-) or "metformin treatment" (+). Flow cytometry was used to define the immunophenotypes of circulating cytotoxic T cells (Tc), circulating helper T cells (Th), and circulating T cells in whole blood. Samples were collected using the BD FACS Verse and BD LSR II.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Researchers have used an ELISA kit to examine how metformin affects cytokine responses, namely IL-17.

Blood collection

For the purpose of immunophenotyping, blood was drawn into a polycarbonate whole blood tube that had been coated with K2EDTA. Serum was separated from blood that was collected in anticoagulant-free polypropylene tubes. The cytokine analysis by ELISA was performed on serum.

Serum Isolation:

We took blood samples in anticoagulant-free polypropylene tubes. The samples were inverted and incubated at room temperature (RT) for 30 to 45 minutes to aid in clotting, and then centrifuged at 2000 RCF for 15 minutes. The serum was centrifuged and then aspirated carefully from the supernatant. Serum was divided up and frozen in cryovials before being kept at -80 degrees Celsius. The whole blood count will be used to isolate the neutrophil and basophil levels. Metformin has an immunomodulatory effect in the treatment of tuberculosis, and these parameters will be evaluated to determine its efficacy in this setting.

Lyse-Wash staining for flow cytometry

We obtained one million cells, or 100 l of blood, in a 12x75 mm FACS tube. After adding the proper quantity of antibodies, the liquid was vortexed. The samples were incubated with the antibody mixture for 5 minutes at RT in the dark. We first diluted the 10X BD FACS Lysing solution (Cat.No.349202) with DDW to make 2 ml of the working 1X solution. The test tubes were incubated for 10 minutes in the dark at room temperature before being centrifuged at 300g for 5 minutes. All of the pellets were smashed by a mild whirlpool. The cells and 2 ml of stain buffer were centrifuged twice at 300g for 5 minutes, and the resulting supernatant was collected. After being resuspended in 500 l of stain buffer, the cells were immediately collected and examined using a flow cytometer.

ELISA

In order to compare IL-17A levels before and after therapy, patients' serum was collected and their blood was drawn into anti-coagulant-free plastic tubes. All chemical reagents, standard working solutions, and patient samples were produced in accordance with SOPs. The standard wells were filled with 50 l of operating solution. Each sample well received forty millilitres. The sample wells contained a mixture of streptavidin-HRP and anti-IL-17 antibody totaling 10 ml. The enclosed plate was incubated for a total of 37 minutes. The plate was cleaned with a wash buffer five times. Allow the wells to rest in the wash buffer (350 l) for one full minute between washing cycles. A paper towel was placed over the dish and used to absorb any excess liquid. Each well first received 50 l of substrate solution A, followed by another 50 l of substrate solution B. The plate went through another round of incubation, this time for 10 minutes at 37 degrees Celsius and in the dark. Blue water in the well immediately turned yellow when 50 litres of Stop Solution were added. The optical density of each well was quickly determined using a 450 nm microplate reader after the stop solution was thoroughly combined.

3. Result and Discussion

Patient characteristics

A total of 120 patients were enrolled, however 24 were disqualified due to insufficient response during the study's follow-up phase. Metformin users were primarily men (62.50%) and had a mean age of 47.56 (n = 48). Patients who did not respond to metformin had a mean age of 49.02 (n = 48), and the majority of them (54.10%) were men. These people had diabetes for an average of nearly five years. Both groups included a same number of patients who had been diagnosed with diabetes for more than five years compared to those who had been diagnosed for less than five years. The average age at which people in the metformin (+) and metformin (-) groups developed diabetes was 41.2 and 42.4 years, respectively. The metformin plus group had a HbA1c% (mean SD) of 7.11 1.43, whereas the metformin minus group had a HbA1c% of 8.26 2.17%. Metformin-positive patients with well-treated diabetes had a HbA1c (mean SD) of 6.43 0.22, whereas those with poorly managed diabetes had a HbA1c (mean SD) of 8.76 1.77. HbA1c% (mean SD) results for treated and uncontrolled DM in non-metformin users were 10.13 2.03 and 6.93 0.98, respectively. Only drug use history (P=.025), literacy (P=.048), and body mass index (P=.028) varied substantially between the two groups at baseline when

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

compared to other factors (Table 1). Metformin (-) had considerably higher direct costs (P .001) owing to disease compared to healthy persons (include research, prescription, transportation, and others). The cost of their care has also contributed considerably to their mounting debt (P =.04). Both groups showed similar trends in the other economic variables (Table 1) that were impacted by the patients' illnesses.

Table 1: Patient's Baseline characteristics

Characteristics	**Metformin(+) (N=48)**	**Metformin (-)(N=48)**	**P value**
Gender			0.53
Female	18 (37.50%)	22 (45.83%)	
Male	30 (62.50%)	26 (54.10%)	
Age (mean±SD)	47.56 ± 6.29	49.02 ±5.79	0.80
<40	11(22.91)	9 (16.66%)	
≥ 40	37 (77.08%)	39 (81.25%)	
Sputum Status			0.39
1+	17 (35.41%)	11 (22.91%)	
2+	19 (39.58%)	22 (45.83%)	
3+	12 (25%)	15 (31.25%)	
Family history of TB			0.82
No	33 (68.75%)	31 (64.58%)	
Yes	15 (31.25%)	17 (35.41%)	
Glycaemic control			0.20
Good (HbA1c<7)	34 (70.83%)	28 (58.33%)	
Poor (HbA1c>7)	14 (29.16%)	20 (41.66%)	
HbA1c % **(**mean±SD)	7.11±1.43	8.26±2.17	
DM Family history			0.52
No	28 (58.33%)	32 (66.66%)	
Yes	20 (41.66%)	16 (33.33%)	
Used history of			0.025*

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Substance			
No	36 (75%)	26 (54.16%)	
Yes	12 (25%)	22 (45.83%)	
Literacy Level			0.048*
Illiterate	8 (16.66%)	16 (33.33%)	
Primary School	10 (20.83%)	18 (37.5%)	
Middle School	12 (25%)	5 (10.41%)	
High School	8 (16.66%)	3 (6.25%)	
Intermediate	6 (12.5%)	4 (8.33%)	
Graduate and professional degree	4 (8.33%)	2 (4.1%)	
Socioeconomic status			0.05
Upper lower	12 (25%)	19 (39.58%)	
Lower	13 (27.08%)	20 (41.66%)	
Upper middle	10 (20.83%)	4 (8.3%)	
Lower middle	11 (22.91%)	4 (8.3%)	
Upper	2 (4.16%)	1 (2.08%)	
BMI			0.028*
<15	4 (8.33%)	11 (22.91%)	
15-18	18 (37.5%)	24 (50%)	
18-23	21 (43.75%)	9 (18.75%)	
>23	5 (10.41%)	4 (8.33%)	
Duration of DM			0.67
< 5 years	16 (33.33%)	19 (39.58%)	
>5 years	32 (66.66%)	29 (60.41%)	

The effects of metformin on patients with TB and T2DM were compared using the Chi-square test, with all results presented as percentages. A significance level of *0.05 was accepted.

Our study team has shown that there is less than previously believed association between literacy and

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

educational attainment and the risk of addiction. Siddiqui et al. (2018) found that TB-DM patients with low levels of education had worse HRQoL ratings in the symptom and sociopsychological & exercise adaption categories at the start of therapy, and our findings corroborate this. The degree of literacy still proved to be the most telling factor. Patients' socioeconomic status was also a predictor of their final HRQoL score after therapy.

Metformin therapy enhances the effectiveness of conventional anti-tuberculardrugs:

It was performed initially (during the first visit) and then weekly (during the subsequent visits) until the conclusion (during the second appointment). Metformin users had a significantly higher rate of negative sputum findings compared to non-users, as determined by weekly testing. On average, it took 3.72.23 weeks for sputum to convert in the metformin (+) group, whereas it took 5.32.47 weeks in the metformin (-) group. Table 2 displays the total number of study participants who had their sputum smear change to metformin (+) or metformin (-).

Table 2: Conversion of Sputum smear in Metformin (+) and Metformin (-)

No of weeks	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**
Metformin (+) (n=30)	4 (13.33%)	8 (26.66%)	12 (40%)	16 (53.33%)	20 (66.66%)	22 (73.33%)	24 (80%)	26 (86.66%0
Metformin (-) (n=30)	2 (6.66%)	3 (10%)	4 (13.33%)	7 (23.33%)	9 (30%)	11 (36.66%)	13 (43.33%)	18 (60%)
P-value	0.67	0.18	0.039*	0.032*	0.009**	0.008**	0.007**	0.0039*

Metformin (+) and metformin (-) in TB+T2DM patients were compared statistically using unpaired t test, and results were provided as percentages. Significant differences (*P0.05)

T cell proportions Change in controlled and uncontrolled diabetics.

Metformin (+) and metformin (-) patients with well-controlled and poorly-controlled diabetes had their CD3, CD4, and CD8 proportions assessed at the conclusion of the intensive phase and at baseline, respectively. Patients whose blood sugar was under control while taking metformin (+) showed significantly higher CD3 (p=0.0005) and CD8 (p=0.0001) levels at the conclusion of the intensive period (Figures 1 and 2).

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine



T cells, Th and Tc cells level increases in TB patients on Metformin therapy with controlled DM. Whole blood of TB patients of Metformin receiver with controlled DM were stained for CD45, CD3 and CD4 by stained lyse wash method at pre and post treatment stages. The blood samples were analyzed for the (**a**) total T cells ($CD45^+CD3^+$), (**b**) total Th cells ($CD45^+CD3^+CD4^+$) and **(c)** total Tc cells ($CD45^+CD3^+CD8^+$).The data depicted as median. $^{***}P \leq 0.0005$, $^{***}P \leq 0.0001$, ns = not significant. Th: Helper T Cells, Tc: Cytotoxic T Cells. MET (+) Pre C DM: Metformin users group Pre-treatment, with controlled DM MET (+) Pre UC DM: Metformin user group Pre-treatment, with uncontrolled DM. Met (+) Post C DM: Metformin user Post-treatment, with controlled DM.MET(+) Post UC DM. Metformin user Post-treatment group with uncontrolled DM.

Figure 1: T cell count in patients with TB+T2DM in controlled and uncontrolled diabetics on metformin therapy



Estimation of T cells, Th and Tc cells levels in Metformin non users with controlled and uncontrolled DM. Whole blood of TB patients of Metformin users with controlled DM and uncontrolled DM were stained for CD45, CD3 and CD4 by stained lyse wash method at pre and post treatment stages. The blood samples were analyzed for the (**a**) total T cells ($CD45^+CD3^+$), (**b**) total Th cells ($CD45^+CD3^+CD4^+$) and **(c)** total Tc cells ($CD45^+CD3^+CD8^+$). The data depicted as median. ns = not significant. Th: Helper T Cells, Tc: Cytotoxic T Cells. MET (-) Pre C DM: Metformin non user group Pre-treatment, with controlled DM MET (-) Pre UC DM: Metformin non user group Pre-treatment, with uncontrolled DM. Met (-) Post C DM: Metformin non user Post-treatment with controlled DM.MET(-) Post UC DM. Metformin non user Post-treatment group with uncontrolled DM.

Figure 2: T cell count in patients with TB+T2DM in controlled and uncontrolled diabetics on other antidiabetic therapy

4. Adverse Events

Adverse events occurred in 9 patients (18.75%) who did not take metformin and in 7 patients (14.58%) who did take it. (Chi-square test, P=.84) There was no discernible difference between the two groups. All of the reported side effects and problems involved the digestive system and were rather minor in nature.

The efficiency of the standard first-line antiTB medicine, such isoniazid, has been demonstrated to be improved by the addition of metformin, which reduces the bacillary load in the lungs (Singhal et al., 2014). It improves the body's defences so that the TB bacilli may be eliminated more rapidly and thoroughly (Singhal, et al., 2014). MET modulates immune response and inflammation in a wide variety of ways. The protective effect is mediated by increased mycobacterial phagosome acidity and increased mROS production by host cells. Activation of the AMP-activated protein kinase (AMPK) is responsible

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

for the anti-inflammatory impact (Singhal A et al., 2014; Yew WW et al., 2019). Having both tuberculosis and type 2 diabetes has no major effect on health-related quality of life. Our study found that towards the end of the second and third visit, patients in the metformin (-) group had significantly worse HRQoL in terms of symptom ratings, overall scores, and other metrics because of reduced cell-mediated immunity.

5. Conclusion:

Overall, the research supports the use of first-line oral antitubercular medicine as a safe and effective conventional therapy for tuberculosis. Isoniazid, rifampin, pyrazinamide, and ethambutol form a drug cocktail that attacks tuberculosis at different points in its life cycle. Adjuvant drugs are added to a standard treatment plan to boost the treatment's effectiveness or lessen the likelihood of adverse effects. Different adjuvant drugs work in different ways, so it's important to discuss treatment options with a doctor and keep a close eye out for adverse reactions and drug combinations.

References:

[1] ADA. Standards of medical care in diabetes-2015. Summary of revisions. Diabetes care 015;38(Suppl):S4.

[2] Lange, C., Dheda, K., Chesov, D., Mandalakas, A. M., & Udwadia, Z. (2019). Management of drug-resistant tuberculosis. The Lancet Respiratory Medicine, 7(9), 820-832.

[3] Mase, S. R., Ramsay, A., Ng, V., Henry, M., Hopewell, P. C., Cunningham, J., & Urbanczik, R. (2013). Yield of serial sputum specimen examinations in the diagnosis of tuberculosis: a systematic review. International Journal of Tuberculosis and Lung Disease, 17(1), 44-52.

[4] Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., ... & Phillips, P. P. (2016). Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases, 63(7), 853-867.

[5] Siddiqui AN, Hussain S, Siddiqui N, Khayyam KU, Tabrez S, Sharma M. Detrimental association between diabetes and tuberculosis: An unresolved double trouble. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018 Nov 1;12(6):1101-7.

[6] Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, Kreiswirth B. Metformin as adjunct antituberculosis therapy. Science translational medicine. 2014 Nov 19;6(263):263ra159.

[7] Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., ... & Villarino, M. E. (2019). Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports: Morbidity and mortality weekly report.

[8] Sugawara I, Yamada H, Mizuno S. Pulmonary tuberculosis in spontaneously diabetic goto kakizaki rats. The Tohoku journal of experimental medicine. 2004;204(2):135-45.

[9] Thillai M, Pollock K, Pareek M, Lalvani A. Interferon-gamma release assays for tuberculosis: current and future applications. Expert Review of Respiratory Medicine. 2014 Feb 1;8(1):67-78.

[10] World Health Organization. (2019). WHO consolidated guidelines on tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment. Geneva: World Health Organization. Retrieved from

[11] Yew WW, Chang KC, Chan DP, Zhang Y. Metformin as a host-directed therapeutic in tuberculosis: is there a promise?. Tuberculosis. 2019 Mar 1;115:76- 80.